Trilostane (cas 13647-35-3)☆
-
Add time:09/07/2019 Source:sciencedirect.com
Trilostane is a reversible, competitive inhibitor of 3 beta-hydroxysteroid dehydrogenase, a key enzyme involved in the synthesis of steroids. It inhibits the conversion of pregnenolone to progesterone, therefore inhibiting the synthesis of progesterone and, therefore, of the adrenal, gonadal, and placental steroids derived from progesterone, including cortisol, aldosterone, androgens, and estrogens. It has been used in the treatment of Cushing's syndrome and in treating postmenopausal breast cancer when relapses have occurred in patients receiving initial estrogen receptor antagonist therapy.
We also recommend Trading Suppliers and Manufacturers of Trilostane (cas 13647-35-3). Pls Click Website Link as below: cas 13647-35-3 suppliers
Prev:Short CommunicationStability of compounded Trilostane (cas 13647-35-3) suspension in cod liver oil
Next:Possible Therapeutic Effect of Trilostane (cas 13647-35-3) in Rodent Models of Inflammation and Nociception) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- The antidepressant-like effects of the 3β-hydroxysteroid dehydrogenase inhibitor Trilostane (cas 13647-35-3) in mice is related to changes in neuroactive steroid and monoamine levels09/24/2019
- Topical reviewMedical Management of Pituitary-Dependent Hyperadrenocorticism: Mitotane versus Trilostane (cas 13647-35-3)09/10/2019
- Short CommunicationExpression of 11β-hydroxysteroid dehydrogenase isoforms in canine adrenal glands treated with Trilostane (cas 13647-35-3)09/09/2019
- Possible Therapeutic Effect of Trilostane (cas 13647-35-3) in Rodent Models of Inflammation and Nociception09/08/2019
- Short CommunicationStability of compounded Trilostane (cas 13647-35-3) suspension in cod liver oil09/06/2019
- Original ArticleIncidence and risk factors for hypoadrenocorticism in dogs treated with Trilostane (cas 13647-35-3)09/05/2019
